Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication.
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine 20 Mar 2019. DOI: 10.1126/scitranslmed.aav0891
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Published online March 13, 2019. DOI: 10.1200/JCO.18.01731 Journal of Clinical Oncology.
BLOG: EPIC IMPACT
EPIC PODCAST: FEATURED
In Episode 2 of Innovations in Cancer, we speak with Lauren Leiman, executive director at BloodPAC, the Blood Profiling Atlas in Cancer (BloodPAC) Consortium, launched October 2017, to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. Lauren discusses the collaborative infrastructure that enables sharing of information between stakeholders in industry, academia, and regulatory agencies with the goal to standardize liquid biopsies to improve outcomes for patients.Listen Now